SCOTTSDALE, Ariz.--(BUSINESS WIRE)--ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBO), will provide its adjuvant candidate, Viprovex®, for nonclinical studies of a Venezuelan equine encephalitis vaccine developed at DynPort Vaccine Company LLC (DVC), a Computer Sciences Corporation (NYSE: CSC) company.
